224 related articles for article (PubMed ID: 21194852)
1. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs.
Treloar C; Hull P; Bryant J; Hopwood M; Grebely J; Lavis Y
Drug Alcohol Depend; 2011 Jul; 116(1-3):52-6. PubMed ID: 21194852
[TBL] [Abstract][Full Text] [Related]
2. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.
Treloar C; Hull P; Dore GJ; Grebely J
Drug Alcohol Rev; 2012 Nov; 31(7):918-24. PubMed ID: 22612899
[TBL] [Abstract][Full Text] [Related]
3. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.
Treloar C; Newland J; Rance J; Hopwood M
J Viral Hepat; 2010 Dec; 17(12):839-44. PubMed ID: 20070504
[TBL] [Abstract][Full Text] [Related]
4. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
Rance J; Newland J; Hopwood M; Treloar C
Soc Sci Med; 2012 Jan; 74(2):245-53. PubMed ID: 22133583
[TBL] [Abstract][Full Text] [Related]
5. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S62-9. PubMed ID: 23884068
[TBL] [Abstract][Full Text] [Related]
6. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C testing and status among opioid substitution treatment clients in New South Wales.
Shand FL; Day C; Rawlinson W; Degenhardt L; Martin NG; Nelson EC
Aust N Z J Public Health; 2014 Apr; 38(2):160-4. PubMed ID: 24690055
[TBL] [Abstract][Full Text] [Related]
8. Injecting drug users' understanding of hepatitis C.
O'Brien S; Day C; Black E; Dolan K
Addict Behav; 2008 Dec; 33(12):1602-5. PubMed ID: 18762384
[TBL] [Abstract][Full Text] [Related]
9. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
[TBL] [Abstract][Full Text] [Related]
10. Knowledge and attitudes towards hepatitis C and injecting drug use among mental-health support workers of a community managed organisation.
Rose G; Cama E; Brener L; Treloar C
Aust Health Rev; 2013 Nov; 37(5):654-9. PubMed ID: 24160716
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus exposure and vaccination in a cohort of people who inject drugs: what has been the impact of targeted free vaccination?
Winter RJ; Dietze PM; Gouillou M; Hellard ME; Robinson P; Aitken CK
J Gastroenterol Hepatol; 2013 Feb; 28(2):314-22. PubMed ID: 23190264
[TBL] [Abstract][Full Text] [Related]
12. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L
J Viral Hepat; 2014 Mar; 21(3):198-207. PubMed ID: 24438681
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia.
Grebely J; Bryant J; Hull P; Hopwood M; Lavis Y; Dore GJ; Treloar C
J Viral Hepat; 2011 Apr; 18(4):e104-16. PubMed ID: 20840350
[TBL] [Abstract][Full Text] [Related]
14. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.
Doab A; Treloar C; Dore GJ
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340
[TBL] [Abstract][Full Text] [Related]
15. Receiving a hepatitis C-positive diagnosis.
Hopwood M; Treloar C
Intern Med J; 2004; 34(9-10):526-31. PubMed ID: 15482264
[TBL] [Abstract][Full Text] [Related]
16. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection.
Hopwood M; Treloar C
Int J Drug Policy; 2007 Oct; 18(5):374-80. PubMed ID: 17854725
[TBL] [Abstract][Full Text] [Related]
17. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus among injecting drug users in Sydney, Australia: prevalence, vaccination and knowledge of status.
Day CA; White B; Dore GJ; van Beek I; Rodgers C; Cunningham P; Wodak A; Maher L
Drug Alcohol Depend; 2010 Apr; 108(1-2):134-7. PubMed ID: 20047803
[TBL] [Abstract][Full Text] [Related]
19. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia.
Treloar C; Rance J; Grebely J; Dore GJ
Drug Alcohol Depend; 2013 Dec; 133(2):529-34. PubMed ID: 23932843
[TBL] [Abstract][Full Text] [Related]
20. Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs.
Park JN; White B; Bates A; Enriquez J; Liao L; Maher L
Drug Alcohol Depend; 2012 Jun; 123(1-3):35-40. PubMed ID: 22071117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
